<?xml version='1.0'?><rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:georss="http://www.georss.org/georss" xmlns:atom="http://www.w3.org/2005/Atom" >
<channel>
	<title><![CDATA[BOL: Related items]]></title>
	<link>https://bioinformaticsonline.com/related/7913?offset=1400</link>
	<atom:link href="https://bioinformaticsonline.com/related/7913?offset=1400" rel="self" type="application/rss+xml" />
	<description><![CDATA[]]></description>
	
	<item>
	<guid isPermaLink="true">https://bioinformaticsonline.com/blog/view/45358/the-variant-everyone-ignored</guid>
	<pubDate>Mon, 05 Oct 2026 12:14:20 -0500</pubDate>
	<link>https://bioinformaticsonline.com/blog/view/45358/the-variant-everyone-ignored</link>
	<title><![CDATA[The Variant Everyone Ignored]]></title>
	<description><![CDATA[<p>Consider a scenario in which a patient's genome has been sequenced. Among billions of DNA bases, a structural alteration may explain the patient's disease. Multiple advanced algorithms analyze the data, yet only one detects the variant, while the others do not. In standard bioinformatics workflows, such a solitary result is often regarded as unreliable and subsequently discarded. Although the solution exists within the data, prevailing computational protocols may overlook it.</p><p>A recent study published in Genome Biology (https://link.springer.com/article/10.1186/s13059-026-04280-y) addressed this challenge by introducing dicast (https://github.com/burgshrimps/dicast), a machine-learning approach for detecting structural variants in short-read sequencing data. Structural variants, such as large deletions, insertions, duplications, and inversions, can have significant biological and clinical implications, yet they are challenging to identify with short-read technologies. Because different detection methods frequently yield divergent results, researchers commonly employ consensus calling, considering a variant valid only if multiple tools detect it. While this approach reduces false positives, it relies on the potentially flawed assumption that the majority is always correct.</p><p>The researchers explored the impact of evaluating the supporting evidence for each variant, rather than simply tallying the number of algorithms that identified it. To establish a ground truth, they analyzed nine genomes using multiple sequencing technologies and 15 detection methods, initially identifying approximately 35 million potential variants. Through extensive filtering, evidence integration, and manual review of over 11,500 variants, they developed a robust benchmark comprising more than 236,000 structural variants. The findings underscored the complexity of the problem: short-read methods detected fewer than half of deletions and less than 10 percent of insertions, with performance declining markedly in repetitive genomic regions. In contrast, long-read technologies demonstrated superior detection capabilities. However, replacing the substantial volume of existing short-read data in clinical and research settings is not immediately feasible. Consequently, the researchers questioned whether short-read data might harbor more information than conventional analytical pipelines currently extract.</p><p>This line of inquiry led to the development of dicast. Rather than merely confirming agreement among multiple tools, dicast identifies patterns in sequencing data, including split and clipped reads, discordant read pairs, alignment characteristics, and the surrounding genomic context. An XGBoost machine-learning model evaluates which combinations of these signals are indicative of genuine structural variants. Thus, the approach shifts from tallying algorithmic consensus to interpreting the underlying evidence.</p><p>The researchers subsequently conducted a targeted evaluation by examining structural variants detected by only a single short-read tool, which are typically missed by consensus-based approaches. dicast successfully recovered approximately 81% of these single-caller deletions, insertions, and duplications. The signals for these variants were present in the data, but conventional filtering methods failed to integrate them effectively.</p><p>The utility of dicast was further demonstrated in cohorts with rare diseases, including congenital limb malformations, atrial fibrillation, and neuromuscular disorders. In one instance, dicast achieved a deletion recall rate of approximately 0.96, compared to 0.74 using consensus calling. The median number of variants requiring manual review was 29 per sample. Among 31 experimentally validated variants that standard filters would have missed, dicast identified 12, whereas consensus calling detected only one.</p><p>Overall, dicast identified approximately 20 percent more potential disease-causing deletions than consensus-based methods. While a 20 percent increase may appear modest, in clinical genomics such improvements can have significant practical implications. Missing a deletion may leave a case unresolved, whereas detecting a structural variant can provide critical diagnostic insights.</p><p>The study does not claim that machine learning has rendered short-read sequencing superior to long-read approaches. Instead, the results underscore the effectiveness of long-read sequencing for structural variant detection. However, dicast highlights a more nuanced perspective: substantial biological information may still be recoverable from the extensive short-read datasets already available.</p><p>The principal lesson extends beyond the detection of structural variants. For many years, bioinformatics pipelines have relied on threshold-based criteria, such as minimum coverage, quality scores, or support from multiple tools. While these rules are useful, biological phenomena do not always conform to rigid checklists; multiple weak signals, when considered collectively, can provide compelling evidence.</p><p>This perspective prompts consideration of the solitary variant: one algorithm identifies it, while several others do not. Traditional consensus techniques might have dismissed it, yet machine learning approaches evaluate the available evidence to determine whether the variant is plausible.</p><p>Occasionally, the most significant variant within a genome is the one that is almost universally overlooked.</p><p>Read more at&nbsp;https://link.springer.com/article/10.1186/s13059-026-04280-y</p>]]></description>
	<dc:creator>BioStar</dc:creator>
</item>
<item>
	<guid isPermaLink="true">https://bioinformaticsonline.com/poll/view/19921/which-of-the-followings-are-the-best-place-to-study-bioinformatics</guid>
	<pubDate>Sun, 28 Dec 2014 00:20:30 -0600</pubDate>
	<link>https://bioinformaticsonline.com/poll/view/19921/which-of-the-followings-are-the-best-place-to-study-bioinformatics</link>
	<title><![CDATA[Which of the followings are the best place to study Bioinformatics ?]]></title>
	<description><![CDATA[<p>Bioinformatics is a major growth area and qualified Bioinformaticians are in high demand. An explosion in biological data has resulted from genome projects, next generation sequencing and other 'omics' techniques. Bioinformatics provides the tools to analyse and exploit such data sets.<br /><br />Can you please suggest me the best place to study bioinformatics ( Grad/PostGrad).</p>]]></description>
	<dc:creator>Reshma Khatun</dc:creator>
</item>
<item>
	<guid isPermaLink="true">https://bioinformaticsonline.com/pages/view/37411/my-commonly-used-commands-in-bioinformatics</guid>
	<pubDate>Thu, 26 Jul 2018 04:58:45 -0500</pubDate>
	<link>https://bioinformaticsonline.com/pages/view/37411/my-commonly-used-commands-in-bioinformatics</link>
	<title><![CDATA[My commonly used commands in Bioinformatics]]></title>
	<description><![CDATA[<p>FYI, I've found it useful to use MUMmer to extract the specific changes that Racon makes, so I can evaluate them individually:</p><pre><code>minimap -t 24 assembly.fasta long_reads.fastq.gz | racon -t 24 long_reads.fastq.gz - assembly.fasta racon_assembly.fasta
nucmer -p nucmer assembly.fasta racon_assembly.fasta
show-snps -C -T -r nucmer.delta
</code></pre><p>This reports Racon's changes in a table. You can exclude indels with the&nbsp;<code>-I</code>&nbsp;option in&nbsp;<code>show-snps</code>.&nbsp;</p><p>This process (Racon -&gt; MUMmer -&gt; SNP table) solves the problem I originally raised in this issue. So as far as I'm concerned, you can close this issue (or keep it open if you still want to implement some kind of variant table).</p>]]></description>
	<dc:creator>Rahul Nayak</dc:creator>
</item>
<item>
	<guid isPermaLink="true">https://bioinformaticsonline.com/news/view/20007/roche-has-acquired-bina-technologies</guid>
	<pubDate>Tue, 30 Dec 2014 09:42:16 -0600</pubDate>
	<link>https://bioinformaticsonline.com/news/view/20007/roche-has-acquired-bina-technologies</link>
	<title><![CDATA[Roche has acquired Bina Technologies !!!]]></title>
	<description><![CDATA[<p>Bina Technologies is a privately held company that provides a big data platform for centralized management and processing of next generation sequencing (NGS) data for the academic and translational research markets.&nbsp; Bina will be integrated into the Roche Sequencing Unit, and will continue to focus on development of their innovative genomic analysis solution.<br /><br />Roche has acquired Bina Technologies, a privately-owned biotech company based in California. The biotech&rsquo;s first product was the Bina Box, a platform for secondary genomic analysis, sequence alignment, and variant calling, but since 2012, it has developed other products and platforms. <br /><br />It is our shared vision with Roche that informatics and data sciences are critical elements of an end-to-end genomics solution. Fast, easy-to-use, scalable, and robust informatics solutions make a big difference in the quality and impact of the work of scientists and researchers. We believe in the future of data-driven, personalized medicine. We are passionate about accelerating that future together with Roche.<br /><br />Financial details of the deal were not disclosed. For Roche, the move is yet another in a string of acquisitions. Last week (December 18), Roche paid $489 million for antibody maker Dutalys. And earlier this month, Roche bought prenatal testing company Ariosa Diagnostics.</p><p>Reference</p><p>http://blog.bina.com/news/bina-technologies-acquired-by-roche?&amp;__hssc=109677338.1.1419953400266&amp;__hstc=109677338.b8350f2729889b08f1325906d5236cd3.1419953400266.1419953400266.1419953400266.1&amp;hsCtaTracking=96cac941-9372-4bbf-bacb-3ca6f1ff8cfd|3fce0f18-835b-4086-9345-388880861732</p><p>http://www.the-scientist.com/?articles.view/articleNo/41750/title/Roche-Buys-Bioinformatics-Firm/</p>]]></description>
	<dc:creator>Jit</dc:creator>
</item>
<item>
	<guid isPermaLink="true">https://bioinformaticsonline.com/bookmarks/view/38063/referee-genome-assembly-quality-scores</guid>
	<pubDate>Sun, 04 Nov 2018 16:44:30 -0600</pubDate>
	<link>https://bioinformaticsonline.com/bookmarks/view/38063/referee-genome-assembly-quality-scores</link>
	<title><![CDATA[Referee: Genome assembly quality scores]]></title>
	<description><![CDATA[<p>Modern genome sequencing technologies provide a succint measure of quality at each position in every read, however all of this information is lost in the assembly process. Referee summarizes the quality information from the reads that map to a site in an assembled genome to calculate a quality score for each position in the genome assembly.</p>
<p>We accomplish this by first calculating genotype likelihoods for every site. For a given site in a diploid genome, there are 10 possible genotypes (AA, AC, AG, AT, CC, CG, CT, GG, GT, TT). Referee takes as input the genotype likelihoods calculated for all 10 genotypes given the called reference base at each position.</p>
<h3>Referee is a program to calculate a quality score for every position in a genome assembly. This allows for easy filtering of low quality sites for any downstream analysis.</h3>
<p>https://github.com/gwct/referee</p><p>Address of the bookmark: <a href="https://gwct.github.io/referee/#" rel="nofollow">https://gwct.github.io/referee/#</a></p>]]></description>
	<dc:creator>Jit</dc:creator>
</item>
<item>
	<guid isPermaLink="true">https://bioinformaticsonline.com/news/view/20331/type-hinting</guid>
	<pubDate>Fri, 09 Jan 2015 22:26:13 -0600</pubDate>
	<link>https://bioinformaticsonline.com/news/view/20331/type-hinting</link>
	<title><![CDATA[Type Hinting]]></title>
	<description><![CDATA[<p>Python creator Guido van Rossum&rsquo;s proposal for static type-checking annotations is inching closer to reality, and the feature has taken on a new name: type hinting.</p><p><img src="http://sdtimes.com/wp-content/uploads/2015/01/0107.sdt-python-typehinting.png" alt="image" width="619" height="219" style="border: 0px; border: 0px;"></p><p>Back in August, van Rossum published a proposal on the Python mailing list recommending type-checking annotations as a valuable feature for the next version of Python to improve the performance of editors and IDEs, linter capabilities, standard notation, and refactoring. Van Rossum&rsquo;s <a href="http://lwn.net/Articles/627558/">latest proposal</a>, posted late last month, outlined plans to publish a Python Enhancement Proposal (PEP) in early January to put the feature now known as type hinting on track for inclusion in Python 3.5, slated for release this September.</p><p>Reference</p><p>https://quip.com/r69HA9GhGa7J</p>]]></description>
	<dc:creator>Pranjali Yadav</dc:creator>
</item>
<item>
	<guid isPermaLink="true">https://bioinformaticsonline.com/bookmarks/view/39726/jackalope-a-swift-versatile-phylogenomic-and-high-throughput-sequencing-simulator</guid>
	<pubDate>Fri, 26 Jul 2019 00:58:12 -0500</pubDate>
	<link>https://bioinformaticsonline.com/bookmarks/view/39726/jackalope-a-swift-versatile-phylogenomic-and-high-throughput-sequencing-simulator</link>
	<title><![CDATA[jackalope: A swift, versatile phylogenomic and high-throughput sequencing simulator]]></title>
	<description><![CDATA[<p><code>jackalope</code> simply and efficiently simulates (i) variants from reference genomes and (ii) reads from both Illumina and Pacific Biosciences (PacBio) platforms. It can either read reference genomes from FASTA files or simulate new ones. Genomic variants can be simulated using summary statistics, phylogenies, Variant Call Format (VCF) files, and coalescent simulations&mdash;the latter of which can include selection, recombination, and demographic fluctuations. <code>jackalope</code> can simulate single, paired-end, or mate-pair Illumina reads, as well as reads from Pacific Biosciences These simulations include sequencing errors, mapping qualities, multiplexing, and optical/PCR duplicates. All outputs can be written to standard file formats.</p>
<p><span>A swift, versatile phylogenomic and high-throughput sequencing simulator </span> <span><a href="https://jackalope.lucasnell.com">https://jackalope.lucasnell.com</a></span></p><p>Address of the bookmark: <a href="https://github.com/lucasnell/jackalope" rel="nofollow">https://github.com/lucasnell/jackalope</a></p>]]></description>
	<dc:creator>Abhimanyu Singh</dc:creator>
</item>

<item>
  <guid isPermaLink='true'>https://bioinformaticsonline.com/opportunity/view/20363/postdoctoral-researcher-in-cancer-systems-biology</guid>
  <pubDate>Mon, 12 Jan 2015 01:44:11 -0600</pubDate>
  <link></link>
  <title><![CDATA[Postdoctoral Researcher in Cancer Systems Biology]]></title>
  <description><![CDATA[
<p>Postdoctoral Researcher in Cancer Systems Biology<br />Department of Oncology, Old Road Campus Research Building, Roosevelt Drive, Oxford<br />Grade 7: £30,434 - £37,394 with a discretionary range to £40,847 p.a.<br />Applications are invited for a Postdoctoral Researcher in Cancer Systems Biology to join a rapidly developing Bioinformatics Research Core group headed by Dr Anastasia Samsonova. The purpose of the role is to develop and deliver integrative approaches to dissect the complexity of cancer as a genomic disease. The research will focus on development and application of effective strategies for mining and integration of complex human *omics datasets and clinical/phenotypic data in cancer studies.</p>

<p>The role sits at the critical interface between genetics and cancer systems biology, and would suit a candidate who is interested in developing a career at the confluence of Statistics/Data Mining/Machine Learning and Biology. Ideally, you will have experience in development of analytical approaches to high-throughput and multivariate data mining and integration gained through a PhD (or equivalent) in a quantitative subject (eg mathematics, statistics, physics, engineering or computer science).</p>

<p>Experience of statistics and/or machine learning techniques is highly desirable as is evidence of prior experience of developing bioinformatics software and/or analysing complex *omics data sets. You will be able to work as part of a team and independently and deliver results to the required standard and schedule. You should be able to organise and prioritise your own work, as well as have excellent communication skills, both written and oral. The post will involve interactions with collaborators from such diverse fields as applied mathematics, statistics, computer science and medicine.</p>

<p>This is a full-time post, fixed-term until 31 March 2017. For informal enquiries, contact Dr Anastasia Samsonova (bioinformatics@oncology.ox.ac.uk).</p>

<p>All applicants must complete a short application form and upload a CV and supporting statement.</p>

<p>The closing date for applications is 12.00 noon on 26 January 2015.</p>

<p>More at https://www.recruit.ox.ac.uk/pls/hrisliverecruit/erq_jobspec_version_4.display_form</p>
]]></description>
</item>
<item>
	<guid isPermaLink="true">https://bioinformaticsonline.com/bookmarks/view/40699/kevler-reference-free-variant-discovery-in-large-eukaryotic-genomes</guid>
	<pubDate>Tue, 28 Jan 2020 03:21:53 -0600</pubDate>
	<link>https://bioinformaticsonline.com/bookmarks/view/40699/kevler-reference-free-variant-discovery-in-large-eukaryotic-genomes</link>
	<title><![CDATA[Kevler: Reference-free variant discovery in large eukaryotic genomes]]></title>
	<description><![CDATA[<p><span>Welcome to&nbsp;</span><span>kevlar</span><span>, software for predicting&nbsp;</span><em>de novo</em><span>&nbsp;genetic variants without mapping reads to a reference genome! kevlar's&nbsp;</span><em>k</em><span>-mer abundance based method calls single nucleotide variants (SNVs), multinucleotide variants (MNVs), insertion/deletion variants (indels), and structural variants (SVs) simultaneously with a single simple model.&nbsp;</span></p>
<p><span>More at&nbsp;<a href="https://kevlar.readthedocs.io/en/latest/">https://kevlar.readthedocs.io/en/latest/</a></span></p>
<p><span><a href="https://www.cell.com/iscience/pdf/S2589-0042(19)30259-7.pdf">https://www.cell.com/iscience/pdf/S2589-0042(19)30259-7.pdf</a></span></p><p>Address of the bookmark: <a href="https://github.com/kevlar-dev/kevlar" rel="nofollow">https://github.com/kevlar-dev/kevlar</a></p>]]></description>
	<dc:creator>Jit</dc:creator>
</item>
<item>
	<guid isPermaLink="true">https://bioinformaticsonline.com/news/view/20439/interactive-market-intelligence</guid>
	<pubDate>Mon, 19 Jan 2015 08:20:38 -0600</pubDate>
	<link>https://bioinformaticsonline.com/news/view/20439/interactive-market-intelligence</link>
	<title><![CDATA[Interactive Market Intelligence]]></title>
	<description><![CDATA[<p>BioInformatics LLC, a premier research and advisory firm serving the life science industry, has launched groundbreaking, dynamic-data presentation platform, Interactive Market Intelligence&mdash; the only cloud-based market research analytics tool for the life science tools industry.<br /><br />Superior to traditional PDF and PowerPoint reports, Interactive Market Intelligence allows end-users to filter, create and export literally thousands of views of data &mdash; all easily obtainable from a set of core metrics that include market, brand, customer and workflow analytics in well-defined segments of the life science market.<br /><br />The Market for Real-Time PCR is the first in a series of topics to be explored using the Interactive Market Intelligence platform. The primary research analysis is based on a survey of 900+ international scientists performing qPCR in their laboratories.<br /><br />Key data findings from "The Market for Real-Time PCR": Global market for qPCR in 2015 is estimated to be $3.6B; The average growth in qPCR throughput is expected to be at 9.8% in 2015; 22% of respondents are highly likely to switch primary suppliers of qPCR products; 50% of respondents use pre-designed primer/probe sets.</p>]]></description>
	<dc:creator>Pranjali Yadav</dc:creator>
</item>

</channel>
</rss>